A Phase II Trial of Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma
- Each treatment cycle lasts 28 days during which participants will take sunitinib orally
every evening before going to sleep.
- During all treatment cycles participants will have a physical exam and will be asked
questions about their general health and specific questions about any problems they may
- A CT or MRI scan will be performed every two cycles (8 weeks) of therapy for the first
6 cycles, then every 3 cycles (12 weeks) after that.
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Response rate (defined as CR+ PR) for patients treated with sunitinib
Susana M. Campos, MD
Dana-Farber Cancer Institute
United States: Food and Drug Administration
|Dana-Farber Cancer Institute||Boston, Massachusetts 02115|
|Massachusetts General Hospital||Boston, Massachusetts 02114-2617|
|Beth-Israel Deaconess Medical Center||Boston, Massachusetts|